Starpharma Holdings Limited (ASX:SPL – Get Free Report) insider Robert Thomas acquired 300,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was bought at an average price of A$0.09 ($0.06) per share, for a total transaction of A$27,900.00 ($18,476.82).
Robert Thomas also recently made the following trade(s):
- On Wednesday, October 23rd, Robert Thomas purchased 200,000 shares of Starpharma stock. The shares were purchased at an average price of A$0.09 ($0.06) per share, for a total transaction of A$18,600.00 ($12,317.88).
Starpharma Stock Performance
The company has a quick ratio of 5.65, a current ratio of 4.94 and a debt-to-equity ratio of 12.55.
About Starpharma
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.
See Also
- Five stocks we like better than Starpharma
- What does consumer price index measure?
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- The Top 5 Performing S&P 500 Stocks YTD in 2024
- What is the S&P/TSX Index?
- L3Harris: Positioned for Gains With Trump’s Defense Policies
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
